Flat Medical has announced the acquisition of InjeQ’s assets, including the IQ-Tip needle system, which received the US Food and Drug Administration (FDA) breakthrough device designation.

The financial specifics of the transaction remain undisclosed.

This acquisition enhances Flat Medical's portfolio with advanced healthcare solutions.

The deal encompasses InjeQ's technology assets and intellectual property, as well as the IQ-Tip system, which employs bioimpedance-based tissue recognition technology to enable precise tissue type differentiation and improve the safety of several medical procedures.

Flat Medical CTO Liyu Lin said: “We are thrilled to welcome InjeQ's groundbreaking technology into the Flat Medical family.

“The IQ-Tip represents a significant advancement in tissue recognition technology, and we're excited to leverage our resources and expertise to bring this innovative solution to healthcare providers and patients worldwide.”

Flat Medical aims to expedite the development and market introduction of the IQ-Tip, ensuring rapid accessibility for healthcare providers and patients.

The company is dedicated to the ongoing enhancement of the technology, with potential applications in a range of medical areas beyond its current usage.

Lin added: “This versatile technology has the capacity to revolutionise a wide range of clinical interventions that require accurate tissue identification.

“We envision its application in various fields of medicine, enhancing precision and patient safety across multiple procedures."

Based in Taipei City, Taiwan, Flat Medical is engaged in the development of safety and precision solutions for pain management, anaesthesia, and intensive and critical care.

The company’s product portfolio includes products such as EpiFaith and EpiFaith CV, which enable medical professionals to ensure successful and secure procedures.